One obvious risk would be blunting of longer term GLP-1 receptor activation. Imagine type 2 diabetes but for ghrelin.
To use an analogy amphetamines have a honeymoon period, and it feels like a lot of people on these weight loss drugs haven’t been on them long enough to get past the honeymoon period and see what the effects are after 10, 20, etc years
It's possible. But, we've had another GLP-1 medication in use for about a decade and a half now - liraglutide. So far, we haven't seen evidence of that occurring.
I don't think anyone who is both informed and sane would suggest that it is impossible that there are negative long term impacts from taking the medication. Just that we have no current indication of them, and that being afraid about a "what if" without any concrete concerns when the alternative is the "continue being in one of the riskiest states possible for human health" is silly.
People don't realize that Ozempic is already a third generation GLP drug, Mounjaro is a 4th, and the try generation drugs are already in wide scale clinical trials.
We do in fact know a lot about how these drugs affect people by now, and as you point out, we have well over a decade of data on them.
To use an analogy amphetamines have a honeymoon period, and it feels like a lot of people on these weight loss drugs haven’t been on them long enough to get past the honeymoon period and see what the effects are after 10, 20, etc years